This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horio, Y. Articles by Takahashi, T. Search for Related Content PubMed PubMed Citation Articles by Horio, Y. Articles by Takahashi, T.

Prognostic Significance of p53 Mutations and 3p Deletions in Primary Resected Non-Small Cell Lung Cancer¹

Laboratories of Immunology [Y. H., K. H., To. T.], Chemotherapy [Ta. T., R. U.], and Epidemiology [T. K.], Aichi Cancer Center Research Institute, and Department of Surgery, Aichi Cancer Center Hospital [M. S.], Chikusa-ku, Nagoya 464; Department of Surgery, National Chubu Hospital, Obu, Aichi 474 [T. N.]; Department of Biochemistry, Cancer Institute, Toshima-ku, Tokyo 170 [K. Y., Y. N.]; and Department of Internal Medicine I, Nagoya University School of Medicine, Nagoya [Y. H., K. S.], Japan

We evaluated the prognostic significance of p53 mutations and an allelic loss of chromosome 3p in 71 patients with non-small cell lung cancer who underwent potentially curative resection. p53 mutations were detected in 35 cases (49%), while 3p deletions were observed in 34 of 70 informative cases (49%). The presence of the p53 mutation was associated with a shortened survival in all patients (P = 0.014 by log rank test), including those in early stages of the disease (stage I or II, n = 48) (P = 0.016 by log rank test). Multivariate analysis by the Cox proportional hazards model also revealed that p53 mutation was an independent yet unfavorable prognostic factor (P = 0.013). Patients with 3p deletion tended to have a poorer prognosis, but not to a statistically significant extent.

¹ This work was supported in part by a Grant-in-Aid for the Comprehensive Ten-Year Strategy for Cancer Research from the Ministry of Health and Welfare, Japan, and Grants-in-Aid for Cancer Research from the Ministry of Education, Science, and Culture and the Ministry of Health and Welfare, Japan.

² To whom requests for reprints should be addressed.

Received 8/14/92. Accepted 11/11/92.

This article has been cited by other articles:

				E. Gallardo, A. Navarro, N. Vinolas, R. M. Marrades, T. Diaz, B. Gel, A. Quera, E. Bandres, J. Garcia-Foncillas, J. Ramirez, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer Carcinogenesis, November 1, 2009; 30(11): 1903 - 1909. [Abstract] [Full Text] [PDF]

				M. Ehrich, J. K. Field, T. Liloglou, G. Xinarianos, P. Oeth, M. R. Nelson, C. R. Cantor, and D. van den Boom Cytosine Methylation Profiles as a Molecular Marker in Non-Small Cell Lung Cancer. Cancer Res., November 15, 2006; 66(22): 10911 - 10918. [Abstract] [Full Text] [PDF]

				T. Fujiwara, N. Tanaka, S. Kanazawa, S. Ohtani, Y. Saijo, T. Nukiwa, K. Yoshimura, T. Sato, Y. Eto, S. Chada, et al. Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1689 - 1699. [Abstract] [Full Text] [PDF]

				P. Luo, Q. He, X. He, Y. Hu, W. Lu, Y. Cheng, and B. Yang Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol. Cancer Ther., April 1, 2006; 5(4): 962 - 968. [Abstract] [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				S. A. Ahrendt, Y. Hu, M. Buta, M. P. McDermott, N. Benoit, S. C. Yang, L. Wu, and D. Sidransky p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study J Natl Cancer Inst, July 2, 2003; 95(13): 961 - 970. [Abstract] [Full Text] [PDF]

				J. D. Hunt, A. Strimas, J. E. Martin, M. Eyer, M. Haddican, B. G. Luckett, B. Ruiz, T. W. Axelrad, W. L. Backes, and E. T. H. Fontham Differences in KRAS Mutation Spectrum in Lung Cancer Cases between African Americans and Caucasians after Occupational or Environmental Exposure to Known Carcinogens Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1405 - 1412. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				J.-Y. Chang, J.-F. Liu, S.-H. Juang, T.-W. Liu, and L.-T. Chen Novel Mutation of Topoisomerase I in Rendering Cells Resistant to Camptothecin Cancer Res., July 1, 2002; 62(13): 3716 - 3721. [Abstract] [Full Text] [PDF]

				E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]

				G. W. Aherne, A. Hardcastle, E. Ward, D. Dobinson, T. Crompton, M. Valenti, L. Brunton, and A. L. Jackman Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules Clin. Cancer Res., September 1, 2001; 7(9): 2923 - 2930. [Abstract] [Full Text] [PDF]

				J. Laudanski, W. Niklinska, T. Burzykowski, L. Chyczewski, and J. Niklinski Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Eur. Respir. J., April 1, 2001; 17(4): 660 - 666. [Abstract] [Full Text] [PDF]

				T. Hirao, H. H. Nelson, T. D. S. Ashok, J. C. Wain, E. J. Mark, D. C. Christiani, J. K. Wiencke, and K. T. Kelsey Tobacco Smoke-induced DNA Damage and an Early Age of Smoking Initiation Induce Chromosome Loss at 3p21 in Lung Cancer Cancer Res., January 1, 2001; 61(2): 612 - 615. [Abstract] [Full Text]

				W. J. M. Hrushesky The Temporal Organization of Life: the Impact of Multi-frequency Non-linear Biologic Time Structure Upon the Host-Cancer Balance Jpn. J. Clin. Oncol., December 1, 2000; 30(12): 529 - 533. [Abstract] [Full Text] [PDF]

				T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063. [Abstract] [Full Text]

				Y. Yatabe, H. Konishi, T. Mitsudomi, S. Nakamura, and T. Takahashi Topographical Distributions of Allelic Loss in Individual Non-Small-Cell Lung Cancers Am. J. Pathol., September 1, 2000; 157(3): 985 - 993. [Abstract] [Full Text] [PDF]

				H. Sano, D. K. Hsu, L. Yu, J. R. Apgar, I. Kuwabara, T. Yamanaka, M. Hirashima, and F.-T. Liu Human Galectin-3 Is a Novel Chemoattractant for Monocytes and Macrophages J. Immunol., August 15, 2000; 165(4): 2156 - 2164. [Abstract] [Full Text] [PDF]

				G. V. Dahl, N. J. Lacayo, N. Brophy, K. Dunussi-Joannopoulos, H. J. Weinstein, M. Chang, B. I. Sikic, and R. J. Arceci Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia J. Clin. Oncol., May 9, 2000; 18(9): 1867 - 1875. [Abstract] [Full Text] [PDF]

				T. Hida, K.-i. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa, and T. Takahashi Cyclooxygenase-2 Inhibitor Induces Apoptosis and Enhances Cytotoxicity of Various Anticancer Agents in Non-Small Cell Lung Cancer Cell Lines Clin. Cancer Res., May 1, 2000; 6(5): 2006 - 2011. [Abstract] [Full Text] [PDF]

				E. F. Patz Jr., J. Connolly, and J. Herndon Prognostic Value of Thoracic FDG PET Imaging After Treatment for Non-Small Cell Lung Cancer Am. J. Roentgenol., March 1, 2000; 174(3): 769 - 774. [Abstract] [Full Text] [PDF]

				V. Skaug, D. Ryberg, E. H. K. M. O. Arab, L. Stangeland, A. O. Myking, and A. Haugen p53 Mutations in Defined Structural and Functional Domains Are Related to Poor Clinical Outcome in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., March 1, 2000; 6(3): 1031 - 1037. [Abstract] [Full Text]

				D. K. Hsu, R.-Y. Yang, Z. Pan, L. Yu, D. R. Salomon, W.-P. Fung-Leung, and F.-T. Liu Targeted Disruption of the Galectin-3 Gene Results in Attenuated Peritoneal Inflammatory Responses Am. J. Pathol., March 1, 2000; 156(3): 1073 - 1083. [Abstract] [Full Text] [PDF]

				I. Murakami, K. Hiyama, S. Ishioka, M. Yamakido, F. Kasagi, and Y. Yokosaki p53 Gene Mutations Are Associated with Shortened Survival in Patients with Advanced Non-small Cell Lung Cancer: An Analysis of Medically Managed Patients Clin. Cancer Res., February 1, 2000; 6(2): 526 - 530. [Abstract] [Full Text]

				M. Esteller, L. Catasus, X. Matias-Guiu, G. L. Mutter, J. Prat, S. B. Baylin, and J. G. Herman hMLH1 Promoter Hypermethylation Is an Early Event in Human Endometrial Tumorigenesis Am. J. Pathol., November 1, 1999; 155(5): 1767 - 1772. [Abstract] [Full Text] [PDF]

				M. C. Tammemagi, J. R. McLaughlin, and S. B. Bull Meta-Analyses of p53 Tumor Suppressor Gene Alterations and Clinicopathological Features in Resected Lung Cancers Cancer Epidemiol. Biomarkers Prev., July 1, 1999; 8(7): 625 - 634. [Abstract] [Full Text]

				S. A. Ahrendt, S. Halachmi, J. T. Chow, L. Wu, N. Halachmi, S. C. Yang, S. Wehage, J. Jen, and D. Sidransky Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array PNAS, June 22, 1999; 96(13): 7382 - 7387. [Abstract] [Full Text] [PDF]

				F. Lonardo, V. Rusch, J. Langenfeld, E. Dmitrovsky, and D. S. Klimstra Overexpression of Cyclins D1 and E Is Frequent in Bronchial Preneoplasia and Precedes Squamous Cell Carcinoma Development Cancer Res., May 1, 1999; 59(10): 2470 - 2476. [Abstract] [Full Text] [PDF]

				J. Geradts, K. M. Fong, P. V. Zimmerman, R. Maynard, and J. D. Minna Correlation of Abnormal RB, p16ink4a, and p53 Expression with 3p Loss of Heterozygosity, Other Genetic Abnormalities, and Clinical Features in 103 Primary Non-Small Cell Lung Cancers Clin. Cancer Res., April 1, 1999; 5(4): 791 - 800. [Abstract] [Full Text] [PDF]

				T. F. Greten and E. M. Jaffee Cancer Vaccines J. Clin. Oncol., March 1, 1999; 17(3): 1047 - 1047. [Abstract] [Full Text] [PDF]

				S. L. Graziano, G. P. Gamble, N. B. Newman, L. Z. Abbott, M. Rooney, S. Mookherjee, M. L. Lamb, L. J. Kohman, and B. J. Poiesz Prognostic Significance of K-ras Codon 12 Mutations in Patients With Resected Stage I and II Non–Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 668 - 668. [Abstract] [Full Text] [PDF]

				G Cox, W P Steward, and K J O'Byrne The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer Thorax, February 1, 1999; 54(2): 169 - 179. [Full Text]

				M. Friedrich, C. Villena–Heinsen, K. Reitnauer, W. Schmidt, W. Tilgen, and J. Reichrath Malignancies of the Uterine Corpus and Immunoreactivity Score of the DNA "Mismatch-Repair" Enzyme Human Mut-S-Homologon-2 J. Histochem. Cytochem., January 1, 1999; 47(1): 113 - 118. [Abstract] [Full Text]

				J. Drach, J. Ackermann, E. Fritz, E. Kromer, R. Schuster, H. Gisslinger, M. DeSantis, N. Zojer, M. Fiegl, S. Roka, et al. Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy Blood, August 1, 1998; 92(3): 802 - 809. [Abstract] [Full Text] [PDF]

				A. J. Hansen, Y.-H. Lee, E. Sterneck, F. J. Gonzalez, and P. I. Mackenzie C/EBPalpha Is a Regulator of the UDP Glucuronosyltransferase UGT2B1 Gene Mol. Pharmacol., June 1, 1998; 53(6): 1027 - 1033. [Abstract] [Full Text]

				T. M. GREATENS, G. A. NIEHANS, J. B. RUBINS, J. JESSURUN, R. A. KRATZKE, M. A. MADDAUS, and D. E. NIEWOEHNER Do Molecular Markers Predict Survival in Non-Small-Cell Lung Cancer? Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1093 - 1097. [Abstract] [Full Text] [PDF]

				A. Umar, J. I. Risinger, W. E. Glaab, K. R. Tindall, J. C. Barrett, and T. A. Kunkel Functional Overlap in Mismatch Repair by Human MSH3 and MSH6 Genetics, April 1, 1998; 148(4): 1637 - 1646. [Abstract] [Full Text] [PDF]

				A. Ichikawa, T. Kinoshita, T. Watanabe, H. Kato, H. Nagai, K. Tsushita, H. Saito, and T. Hotta Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma N. Engl. J. Med., August 21, 1997; 337(8): 529 - 534. [Abstract] [Full Text] [PDF]

				W. G. Tatton Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration Neurology, December 1, 1996; 47(6_Suppl_3): 171S - 183S. [Abstract] [Full Text] [PDF]

				G. A. Rosenberg, J. E. Dencoff, N. Correa Jr., M. Reiners, and C. C. Ford Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury Neurology, June 1, 1996; 46(6): 1626 - 1632. [Abstract] [Full Text] [PDF]

				P.H.E. Hilkens, J. Verweij, G. Stoter, Ch.J. Vecht, W. L.J. van Putten, and M. J. van den Bent Peripheral neurotoxicity induced by docetaxel Neurology, January 1, 1996; 46(1): 104 - 108. [Abstract] [Full Text] [PDF]

				J. C. Nesbitt, J. B. Putnam Jr, G. L. Walsh, J. A. Roth, and C. F. Mountain Survival in Early-Stage Non--Small Cell Lung Cancer Ann. Thorac. Surg., August 1, 1995; 60(2): 466 - 472. [Abstract] [Full Text]

				B. Passlick, J. R. Izbicki, K. Haussinger, O. Thetter, and K. Pantel Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer J. Thorac. Cardiovasc. Surg., June 1, 1995; 109(6): 1205 - 1211. [Abstract] [Full Text]

				S Kwok, S Y Chang, J J Sninsky, and A Wang A guide to the design and use of mismatched and degenerate primers. Genome Res., February 1, 1994; 3(4): S39 - S47. [PDF]

				P. F. Bongiorno, R. I. Whyte, E. J. Lesser, J. H. Moore, M. B. Orringer, and D. G. Beer Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 590 - 595. [Abstract] [Full Text]

				H. Symonds, L. Krall, L. Remington, M. Saenz Robles, T. Jacks, and T. Van Dyke p53-Dependent Apoptosis In Vivo: Impact of p53 Inactivation on Tumorigenesis Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 247 - 257. [Abstract] [PDF]

				S.W. Lowe, S. Bodis, N. Bardees, A. McClatchey, L. Remington, H.E. Ruley, D.E. Fisher, T. Jacks, J. Pelletier, and D.E. Housman Apoptosis and the Prognostic Significance of p53 Mutation Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 419 - 426. [Abstract] [PDF]

				A.F. Gazdar, S. Bader, J. Hung, Y. Kishimoto, Y. Sekido, K. Sugio, A. Virmani, J. Fleming, D.P. Carbone, and J.D. Minna Molecular Genetic Changes Found in Human Lung Cancer and Its Precursor Lesions Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 565 - 572. [Abstract] [PDF]